CoChat

Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells

Vavassori, Valentina, Ferrari, Samuele, Beretta, Stefano, Asperti, Claudia, Albano, Luisa, Annoni, Andrea, Gaddoni, Chiara, Varesi, Angelica, Soldi, Monica, Cuomo, Alessandro, Bonaldi, Tiziana, Radrizzani, Marina, Merelli, Ivan, Naldini, Luigi · 2023 · Blood
Cited by 100

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Ex vivo gene editing in T cells and hematopoietic stem/progenitor cells (HSPCs) holds promise for treating diseases. Gene editing encompasses the delivery of a programmable editor RNA or ribonucleoprotein, often achieved ex vivo via electroporation, and when aiming for homology-driven correction of a DNA template, often provided by viral vectors together with a nuclease editor. Although HSPCs activate a robust p53-dependent DNA damage response upon nuclease-based editing, the responses triggered in T cells remain poorly characterized. Here, we performed comprehensive multiomics analyses and found that electroporation is the main culprit of cytotoxicity in T cells, causing death and cell cycle delay, perturbing metabolism, and inducing an inflammatory response. Nuclease RNA delivery using lipid nanoparticles (LNPs) nearly abolished cell death and ameliorated cell growth, improving tolerance to the procedure and yielding a higher number of edited cells compared with using electroporation. Transient transcriptomic changes upon LNP treatment were mostly caused by cellular loading with exogenous cholesterol, whose potentially detrimental impact could be overcome by limiting exposure. Notably, LNP-based HSPC editing dampened p53 pathway induction and supported higher clonogenic activity and similar or higher reconstitution by long-term repopulating HSPCs compared with electroporation, reaching comparable editing efficiencies. Overall, LNPs may allow efficient and harmless ex vivo gene editing in hematopoietic cells for the treatment of human diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2022019333

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 43

  1. Naldini, 2019, Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives, EMBO Mol Med, 11, e9958, 10.15252/emmm.201809958 · DOI · Paper page
  2. Ferrari, 2021, Gene editing of hematopoietic stem cells: hopes and hurdles toward clinical translation, Front Genome Ed, 3, 618378, 10.3389/fgeed.2021.618378 · DOI
  3. June, 2018, Chimeric antigen receptor therapy, N Engl J Med, 379, 64, 10.1056/NEJMra1706169 · DOI · Paper page
  4. Lin, 2021, Advances in universal CAR-T cell therapy, Front Immunol, 12, 744823, 10.3389/fimmu.2021.744823 · DOI · Paper page
  5. Lidonnici, 2018, Gene therapy and gene editing strategies for hemoglobinopathies, Blood Cells Mol Dis, 70, 87, 10.1016/j.bcmd.2017.12.001 · DOI
  6. Pavel-Dinu, 2019, Gene correction for SCID-X1 in long-term hematopoietic stem cells, Nat Commun, 10, 1634, 10.1038/s41467-019-09614-y · DOI · Paper page
  7. Sweeney, 2017, Targeted repair of CYBB in X-CGD iPSCs requires retention of intronic sequences for expression and functional correction, Mol Ther, 25, 321, 10.1016/j.ymthe.2016.11.012 · DOI · Paper page
  8. Vavassori, 2021, Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper-IgM syndrome, EMBO Mol Med, 13, e13545, 10.15252/emmm.202013545 · DOI
  9. Kuo, 2018, Site-specific gene editing of human hematopoietic stem cells for X-linked hyper-IgM syndrome, Cell Rep, 23, 2606, 10.1016/j.celrep.2018.04.103 · DOI · Paper page
  10. Hubbard, 2016, Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome, Blood, 127, 2513, 10.1182/blood-2015-11-683235 · DOI · Paper page
  11. Lombardo, 2011, Site-specific integration and tailoring of cassette design for sustainable gene transfer, Nat Methods, 8, 861, 10.1038/nmeth.1674 · DOI · Paper page
  12. Ferrari, 2020, Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking, Nat Biotechnol, 38, 1298, 10.1038/s41587-020-0551-y · DOI · Paper page
  13. Batista Napotnik, 2012, Nanosecond electric pulses cause mitochondrial membrane permeabilization in Jurkat cells, Bioelectromagnetics, 33, 257, 10.1002/bem.20707 · DOI · Paper page
  14. Batista Napotnik, 2021, Cell death due to electroporation – a review, Bioelectrochemistry, 141, 107871, 10.1016/j.bioelechem.2021.107871 · DOI · Paper page
  15. Atsavapranee, 2021, Delivery technologies for T cell gene editing: applications in cancer immunotherapy, EBioMedicine, 67, 103354, 10.1016/j.ebiom.2021.103354 · DOI
  16. Gaudelli, 2020, Directed evolution of adenine base editors with increased activity and therapeutic application, Nat Biotechnol, 38, 892, 10.1038/s41587-020-0491-6 · DOI · Paper page
  17. Gattinoni, 2017, T memory stem cells in health and disease, Nat Med, 23, 18, 10.1038/nm.4241 · DOI · Paper page
  18. Danaei, 2018, Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems, Pharmaceutics, 10, 57, 10.3390/pharmaceutics10020057 · DOI · Paper page
  19. Perl, 2004, Mitochondrial hyperpolarization: a checkpoint of T-cell life, death and autoimmunity, Trends Immunol, 25, 360, 10.1016/j.it.2004.05.001 · DOI · Paper page
  20. Bietz, 2017, Cholesterol metabolism in T cells, Front Immunol, 8, 1664, 10.3389/fimmu.2017.01664 · DOI
  21. Armstrong, 2010, ATP-binding cassette transporter G1 negatively regulates thymocyte and peripheral lymphocyte proliferation, J Immunol, 184, 173, 10.4049/jimmunol.0902372 · DOI · Paper page
  22. York, 2015, Limiting cholesterol biosynthetic flux spontaneously engages type I IFN signaling, Cell, 163, 1716, 10.1016/j.cell.2015.11.045 · DOI · Paper page
  23. Pavani, 2020, Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins, Nat Commun, 11, 3778, 10.1038/s41467-020-17552-3 · DOI · Paper page
  24. Pattabhi, 2019, In vivo outcome of homology-directed repair at the HBB gene in HSC using alternative donor template delivery methods, Mol Ther Nucleic Acids, 17, 277, 10.1016/j.omtn.2019.05.025 · DOI · Paper page
  25. Romero, 2019, Editing the sickle cell disease mutation in human hematopoietic stem cells: comparison of endonucleases and homologous donor templates, Mol Ther, 27, 1389, 10.1016/j.ymthe.2019.05.014 · DOI · Paper page
  26. Steinert, 2021, Mitochondrial metabolism regulation of T cell–mediated immunity, Annu Rev Immunol, 39, 395, 10.1146/annurev-immunol-101819-082015 · DOI
  27. Desdín-Micó, 2018, Mitochondrial activity in T cells, Mitochondrion, 41, 51, 10.1016/j.mito.2017.10.006 · DOI · Paper page
  28. Chyu, 2014, Cholesterol lowering modulates T cell function in vivo and in vitro, PLoS One, 9, e92095, 10.1371/journal.pone.0092095 · DOI
  29. Surls, 2012, Increased membrane cholesterol in lymphocytes diverts T-cells toward an inflammatory response, PLoS One, 7, e38733, 10.1371/journal.pone.0038733 · DOI
  30. Gao, 2014, Regulation of high-density lipoprotein on hematopoietic stem/progenitor cells in atherosclerosis requires scavenger receptor type BI expression, Arterioscler Thromb Vasc Biol, 34, 1900, 10.1161/ATVBAHA.114.304006 · DOI
  31. Yvan-Charvet, 2010, ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation, Science, 328, 1689, 10.1126/science.1189731 · DOI · Paper page
  32. Westerterp, 2012, Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways, Cell Stem Cell, 11, 195, 10.1016/j.stem.2012.04.024 · DOI · Paper page
  33. Ghassemi, 2022, Rapid manufacturing of non-activated potent CAR T cells, Nat Biomed Eng, 6, 118, 10.1038/s41551-021-00842-6 · DOI · Paper page
  34. Ghassemi, 2020, Enhancing chimeric antigen receptor T cell anti-tumor function through advanced media design, Mol Ther Methods Clin Dev, 18, 595, 10.1016/j.omtm.2020.07.008 · DOI · Paper page
  35. Xu, 2020, Challenges and clinical strategies of CAR T-cell therapy for acute lymphoblastic leukemia: overview and developments, Front Immunol, 11, 569117, 10.3389/fimmu.2020.569117 · DOI
  36. Honaker, 2020, Gene editing to induce FOXP3 expression in human CD4+ T cells leads to a stable regulatory phenotype and function, Sci Transl Med, 12, 6422, 10.1126/scitranslmed.aay6422 · DOI
  37. Goodwin, 2020, CRISPR-based gene editing enables FOXP3 gene repair in IPEX patient cells, Sci Adv, 6, eaaz0571, 10.1126/sciadv.aaz0571 · DOI · Paper page
  38. Fox, 2022, Therapeutic gene editing of T cells to correct CTLA-4 insufficiency, Sci Transl Med, 14, eabn5811, 10.1126/scitranslmed.abn5811 · DOI
  39. Goldman, 2008, Characterization of primitive hematopoietic cells from patients with dyskeratosis congenita, Blood, 111, 4523, 10.1182/blood-2007-10-120204 · DOI · Paper page
  40. Croop, 2001, Mobilization and collection of peripheral blood CD34+ cells from patients with Fanconi anemia, Blood, 98, 2917, 10.1182/blood.V98.10.2917 · DOI · Paper page
  41. Six, 2020, Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programs, Blood, 135, 1219, 10.1182/blood.2019002350 · DOI · Paper page
  42. Omer-Javed, 2022, Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells, Cell, 185, 2248, 10.1016/j.cell.2022.04.039 · DOI
  43. Samuelson, 2021, Multiplex CRISPR/Cas9 genome editing in hematopoietic stem cells for fetal hemoglobin reinduction generates chromosomal translocations, Mol Ther Methods Clin Dev, 23, 507, 10.1016/j.omtm.2021.10.008 · DOI

Cited by

See all 100

Metadata

Authors
Vavassori, V., Ferrari, S., Beretta, S., Asperti, C., Albano, L., Annoni, A., Gaddoni, C., Varesi, A., Soldi, M., Cuomo, A., Bonaldi, T., Radrizzani, M., Merelli, I., & Naldini, L.
Affiliations
  • 1San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy
  • 3Department of Molecular Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
Venue
Blood
Published
2023-08-31
Volume
142
Issue
9
Pages
812-826
ISSN
  • 0006-4971
  • 1528-0020
Cited by
100
References
18
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells. https://app.cochat.ai/papers/10.1182/blood.2022019333
The paper
Vavassori, V., Ferrari, S., Beretta, S., Asperti, C., Albano, L., Annoni, A., Gaddoni, C., Varesi, A., Soldi, M., Cuomo, A., Bonaldi, T., Radrizzani, M., Merelli, I., & Naldini, L. (2023). Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells. Blood. https://doi.org/10.1182/blood.2022019333

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.